GT200600044A - Polimorfo cci-779 y su uso - Google Patents

Polimorfo cci-779 y su uso

Info

Publication number
GT200600044A
GT200600044A GT200600044A GT200600044A GT200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A
Authority
GT
Guatemala
Prior art keywords
cci
polymorph
hydrometil
sirolimus
rapamycin
Prior art date
Application number
GT200600044A
Other languages
English (en)
Spanish (es)
Inventor
Subodh S Deshmukh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600044A publication Critical patent/GT200600044A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GT200600044A 2005-02-09 2006-02-07 Polimorfo cci-779 y su uso GT200600044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09

Publications (1)

Publication Number Publication Date
GT200600044A true GT200600044A (es) 2006-11-09

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600044A GT200600044A (es) 2005-02-09 2006-02-07 Polimorfo cci-779 y su uso

Country Status (19)

Country Link
US (1) US7442707B2 (enExample)
EP (1) EP1856130A1 (enExample)
JP (1) JP2008530090A (enExample)
KR (1) KR20070107030A (enExample)
CN (1) CN101115759A (enExample)
AR (1) AR052479A1 (enExample)
AU (1) AU2006213061A1 (enExample)
BR (1) BRPI0607932A2 (enExample)
CA (1) CA2595766A1 (enExample)
CR (1) CR9257A (enExample)
GT (1) GT200600044A (enExample)
IL (1) IL184560A0 (enExample)
MX (1) MX2007009590A (enExample)
NO (1) NO20073725L (enExample)
PE (1) PE20060996A1 (enExample)
RU (1) RU2007129264A (enExample)
TW (1) TW200638932A (enExample)
WO (1) WO2006086172A1 (enExample)
ZA (1) ZA200706628B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
KR20080077618A (ko) * 2005-12-07 2008-08-25 와이어쓰 정제된 결정체 cci-779 의 제조 방법
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
PT1658295E (pt) * 2003-08-07 2007-09-25 Wyeth Corp Síntese regiosselectiva de cci-779
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
EP1737869A1 (en) * 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives

Also Published As

Publication number Publication date
US20060178392A1 (en) 2006-08-10
JP2008530090A (ja) 2008-08-07
NO20073725L (no) 2007-09-05
WO2006086172A1 (en) 2006-08-17
CN101115759A (zh) 2008-01-30
CA2595766A1 (en) 2006-08-17
AU2006213061A1 (en) 2006-08-17
MX2007009590A (es) 2007-09-12
KR20070107030A (ko) 2007-11-06
RU2007129264A (ru) 2009-03-20
AR052479A1 (es) 2007-03-21
US7442707B2 (en) 2008-10-28
TW200638932A (en) 2006-11-16
BRPI0607932A2 (pt) 2016-11-08
EP1856130A1 (en) 2007-11-21
CR9257A (es) 2007-11-23
IL184560A0 (en) 2007-10-31
PE20060996A1 (es) 2006-11-13
ZA200706628B (en) 2010-01-27

Similar Documents

Publication Publication Date Title
WO2007028135A3 (en) Imidazopyridine compounds
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
BRPI0720993B8 (pt) usos de compostos análogos de ciclopamina
CL2010000320A1 (es) Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer.
EP2662353A3 (en) Antibacterial agents
GT200500085A (es) Sintesis regioespecifica de derivados de 42-ester de rapamicina
WO2009060835A1 (ja) 新規ユビキリン結合性小分子
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2004066912A3 (en) Anti-inflammatory compositions and uses thereof
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
WO2007061923A3 (en) Glucokinase activators
BRPI0613429A2 (pt) inibidores de histona desacetilase
CO6541645A2 (es) Compuestos de indol y su uso farmaceutico
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
CO6260093A2 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CR10628A (es) Compuestos quimicos
ECSP11011181A (es) Compuestos orgánicos
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
UY28695A1 (es) Derivados de difenilazetidona